These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 16964988)

  • 21. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of antithrombotic drugs in older people.
    Tufano A; Cerbone AM; Di Minno G
    Minerva Med; 2002 Feb; 93(1):13-26. PubMed ID: 11850611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
    Reeves D; Liu CY
    J Oncol Pharm Pract; 2010 Mar; 16(1):27-31. PubMed ID: 19401307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current concepts for the prevention of venous thromboembolism.
    Bramlage P; Pittrow D; Kirch W
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():4-11. PubMed ID: 15701142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of venous thromboembolism in cancer patients.
    Lee AY
    Thromb Res; 2001 Jun; 102(6):V195-208. PubMed ID: 11516453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors.
    Eriksson BI; Dahl OE
    Drugs; 2004; 64(6):577-95. PubMed ID: 15018589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low molecular weight heparins in the long-term treatment of venous thromboembolism.
    Liapis CD; Daskalopoulos ME; Daskalopoulou SE
    J Cardiovasc Surg (Torino); 2002 Aug; 43(4):495-500. PubMed ID: 12124561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism.
    Ornstein DL; Hong-Dice YG; Papini JR
    Mil Med; 2001 Jul; 166(7):593-601. PubMed ID: 11469031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.
    Nutescu EA; Wittkowsky AK; Dobesh PP; Hawkins DW; Dager WE
    Ann Pharmacother; 2006 Sep; 40(9):1558-71. PubMed ID: 16912250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of Venous Thromboembolism in the Elderly: A Review of the Non-Vitamin K Oral Anticoagulants.
    Bethishou L; Gregorian T; Won K; Lopez K; Tsu LV
    Consult Pharm; 2018 May; 33(5):248-261. PubMed ID: 29789046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Traditional versus modern anticoagulant strategies: summary of the literature.
    Nutescu E; Racine E
    Am J Health Syst Pharm; 2002 Oct; 59(20 Suppl 6):S7-14. PubMed ID: 12400244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety profile of different low-molecular weight heparins used at therapeutic dose.
    Gouin-Thibault I; Pautas E; Siguret V
    Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological prevention of venous thromboembolism in medical patients at risk.
    Wolozinsky M; Yavin YY; Cohen AT
    Am J Cardiovasc Drugs; 2005; 5(6):409-15. PubMed ID: 16259529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E; Rocha E
    Vasc Health Risk Manag; 2013; 9():207-28. PubMed ID: 23674896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacoeconomics of thrombosis management.
    Hawkins D
    Pharmacotherapy; 2004 Jul; 24(7 Pt 2):95S-99S. PubMed ID: 15317405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of venous thrombosis in cancer patients: practical aspects].
    Laza-Achille M; Desruennes E; Di Palma M
    Bull Cancer; 2006 Mar; 93(3):271-81. PubMed ID: 16567314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hirudins for prophylaxis and treatment of venous thromboembolism.
    Prisco D; Falciani M; Antonucci E; Gensini GF
    Semin Thromb Hemost; 2001 Oct; 27(5):543-9. PubMed ID: 11668426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venous thromboembolism: identifying patients at risk and establishing prophylaxis.
    Shirvanian S; Tapson VF
    Curr Med Res Opin; 2015 Dec; 31(12):2297-311. PubMed ID: 26414590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.